Bibliographic Details
| Title: |
Eculizumab as a promising treatment in thymoma-associated myasthenia gravis |
| Authors: |
Valentina Vélez-Santamaría, Velina Nedkova, Laura Díez, Christian Homedes, M. Antonia Alberti, Carlos Casasnovas |
| Source: |
Therapeutic Advances in Neurological Disorders, Vol 13 (2020) |
| Publisher Information: |
SAGE Publishing, 2020. |
| Publication Year: |
2020 |
| Collection: |
LCC:Neurology. Diseases of the nervous system |
| Subject Terms: |
Neurology. Diseases of the nervous system, RC346-429 |
| More Details: |
Myasthenia gravis is a chronic autoimmune disorder caused by antibodies directed against the neuromuscular junction. Some patients may have an associated thymoma, which confers a worse prognosis. Eculizumab, a monoclonal antibody that inhibits the activation of terminal complement, has recently been approved for the treatment of refractory generalized myasthenia gravis. This is an early case report of thymoma-associated refractory myasthenia gravis successfully treated with eculizumab in a real-world setting. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1756-2864
17562864 |
| Relation: |
https://doaj.org/toc/1756-2864 |
| DOI: |
10.1177/1756286420932035 |
| Access URL: |
https://doaj.org/article/48f75920ab2b4b8580922b56d5bacfbe |
| Accession Number: |
edsdoj.48f75920ab2b4b8580922b56d5bacfbe |
| Database: |
Directory of Open Access Journals |
